Sector
PharmaceuticalsOpen
₹203Prev. Close
₹204.4Turnover(Lac.)
₹48.54Day's High
₹209.25Day's Low
₹19752 Week's High
₹232.8552 Week's Low
₹62Book Value
₹23.87Face Value
₹10Mkt Cap (₹ Cr.)
236.02P/E
38.71EPS
5.28Divi. Yield
06 Sep 2023
12:00 AM
BookCloser
6 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
6 Sep 2023
12:00 AM
AGM
Announcement Date: 06 Sep, 2023
26 Dec 2023
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 10 | 10 | 8.5 | 5.9 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -13.07 | -17.58 | -53.39 | -54.81 |
Net Worth | -3.07 | -7.58 | -44.89 | -48.91 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 25.09 | 16.35 | 17.95 | 32.66 |
yoy growth (%) | 53.46 | -8.92 | -45.02 | -71.71 |
Raw materials | -14.8 | -9.06 | -25.38 | -28.15 |
As % of sales | 58.98 | 55.43 | 141.36 | 86.19 |
Employee costs | -2.49 | -2.61 | -2.96 | -2.77 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1.41 | -1.8 | -53.37 | -26.41 |
Depreciation | -0.85 | -1.07 | -1.19 | -1.19 |
Tax paid | 0 | 0.1 | 0.31 | 0.19 |
Working capital | 2.96 | 8.78 | -54.83 | -23.02 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 53.46 | -8.92 | -45.02 | -71.71 |
Op profit growth | -744.32 | -99.36 | 124.45 | 321.48 |
EBIT growth | -233.46 | -97.82 | 144.81 | 251.42 |
Net profit growth | -183.08 | -96.78 | 102.35 | 79.09 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Ashwin Khemka
Independent Director
Mrunmai M Sarvankar
Independent Director
Monika Singhania
Executive Director
Srivardhan Ashwani Khemka
Company Sec. & Compli. Officer
Pooja Vijay Gohil
Additional Director
ABHAY SHAH
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Sanjivani Paranteral Ltd
Summary
Sanjivani Paranteral Ltd is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades. The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun.Incorporated as a public limited company in Oct.94, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry. The Company has been involved in the manufacturing of pharmaceutical medicines. The Companys products includes oral solids, small volume parenteral and sterile powder formulations.The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative. The installed capacities for its products will be, 150 lac pa each for liquid vials and powder vials and 73 lac pa for its ampoules, taking the total capacity to 375 lac pa. The company came out with a public issue in Jan.96 to part-finance the project.The promoters have received firm inquiries from reputed pharmaceutical companies like Merind, Lupin Laboratories and USV for the first year production of liquid vials and ampules.During the year 1998-99, the Company has been approved by the WHO GMP Certificate. The Company is hop
Read More
What is the Sanjivani Paranteral Ltd share price today?
The Sanjivani Paranteral Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹202 today.
What is the Market Cap of Sanjivani Paranteral Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanjivani Paranteral Ltd is ₹236.02 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Sanjivani Paranteral Ltd?
The PE and PB ratios of Sanjivani Paranteral Ltd is 38.71 and 8.56 as of 22 Jul ‘24
What is the 52 Week High and Low of Sanjivani Paranteral Ltd?
The 52-week high/low is the highest and lowest price at which a Sanjivani Paranteral Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sanjivani Paranteral Ltd is ₹62 and ₹232.85 as of 22 Jul ‘24
What is the CAGR of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd's CAGR for 5 Years at 90.30%, 3 Years at 100.52%, 1 Year at 219.72%, 6 Month at 22.40%, 3 Month at 14.86% and 1 Month at 18.36%.
What is the shareholding pattern of Sanjivani Paranteral Ltd?
The shareholding pattern of Sanjivani Paranteral Ltd is as follows:
Promoters - 27.67 %
Institutions - 9.70 %
Public - 62.63 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
